Dapagliflozin Lowers HbA1c, Systolic Blood Pressure and Serum Uric Acid in Patients With Type 2 Diabetes and Hypertension, Regardless of Class of Concomitant Antihypertensive Therapy

被引：0
|
作者：
Weber, Michael A.
Mansfield, Traci A.
Iqbal, Nayyar
Parikh, Shamik J.
Ptaszynska, Agata
机构：
来源：
CIRCULATION | 2014年 / 130卷
关键词：
Diabetes (Type II); Antihypertensive agents; Blood pressure; Hypertension; Glucose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13640
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combined HbA1c and Systolic Blood Pressure Reduction With Dapagliflozin in Patients With Both Inadequately Controlled Type 2 Diabetes Mellitus and Hypertension
    Weber, Michael A.
    List, James
    Mansfield, Traci A.
    Parikh, Shamik J.
    Ptaszynska, Agata
    CIRCULATION, 2014, 130
  • [2] Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension
    Cherney, David
    Cooper, Mark
    Tikkanen, Ilkka
    Crowe, Susanne
    Johansen, Odd Erik
    Lund, Soren S.
    Woerle, Hans J.
    Broedl, Uli C.
    Hach, Thomas
    CIRCULATION, 2014, 130
  • [3] Practice pearl: the effect of canagliflozin on HbA1c and blood pressure in patients with type 2 diabetes mellitus
    Guthrie, Robert M.
    POSTGRADUATE MEDICINE, 2015, 127 (08) : 783 - 785
  • [4] Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, Katherine
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Inman, Doreen
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 313 - 318
  • [5] Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
    Sjostrom, C. David
    Johansson, Peter
    Ptaszynska, Agata
    List, James
    Johnsson, Eva
    DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (05) : 352 - 358
  • [6] HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics
    Foo, Valencia
    Quah, Joanne
    Cheung, Gemmy
    Tan, Ngiap Chun
    Ma Zar, Kyi Lin
    Chan, Choi Mun
    Lamoureux, Ecosse
    Wong, Tien Yin
    Tan, Gavin
    Sabanayagam, Charumathi
    JOURNAL OF DIABETES, 2017, 9 (02) : 200 - 207
  • [7] Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide
    Paul, S.
    Best, J.
    Klein, K.
    Han, J.
    Maggs, D.
    DIABETES OBESITY & METABOLISM, 2012, 14 (09) : 826 - 834
  • [8] Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
    Ertugrul, Derun Taner
    Kan, Erdal
    Tura, Cigdem Bahadir
    Tugtekin, Haci Bayram
    Ayakta, Hayati
    Celebioglu, Mehmet
    Yilmaz, Ceren
    Utebay, Onur
    Yetkin, Ilhan
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2022, 42 (01) : 147 - 160
  • [9] Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
    Derun Taner Ertugrul
    Erdal Kan
    Cigdem Bahadir Tura
    Haci Bayram Tugtekin
    Hayati Ayakta
    Mehmet Celebioglu
    Ceren Yılmaz
    Onur Utebay
    Ilhan Yetkin
    International Journal of Diabetes in Developing Countries, 2022, 42 : 147 - 160
  • [10] Empagliflozin Reduces Systolic Blood Pressure in Dipper and Non-Dipper Patients with Type 2 Diabetes and Hypertension
    Chilton, Robert
    Tikkanen, Ilkka
    Crowe, Susanne
    Johansen, Odd Erik
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    CIRCULATION, 2014, 130
12345